Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor

O. V. Sintsova; E. V. Leychenko; I. N. Gladkikh; A. P. Kalinovskii; M. M. Monastyrnaya; E. P. Kozlovskaya

doi:10.1134/S1607672919060097

Magnificamide Is a New Effective Mammalian α-Amylase Inhibitor

Авторлар: Sintsova O.V.¹, Leychenko E.V.¹, Gladkikh I.N.¹, Kalinovskii A.P.¹^,2, Monastyrnaya M.M.¹, Kozlovskaya E.P.¹
Мекемелер:
1. Elyakov Pacific Institute of Bioorganic Chemistry, Far Eastern Branch, Russian Academy of Sciences
2. School of Natural Sciences, Far Eastern Federal University
Шығарылым: Том 489, № 1 (2019)
Беттер: 385-387
Бөлім: Biochemistry, Biophysics, and Molecular Biology
URL: https://journals.rcsi.science/1607-6729/article/view/213120
DOI: https://doi.org/10.1134/S1607672919060097
ID: 213120

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат
Рұқсат жабық

Рұқсат берілді
Рұқсат жабық

Тек жазылушылар үшін

Аннотация
Авторлар туралы
Әдебиет тізімі
Қосымша файлдар
Статистика

Аннотация

Recombinant analogue of the sea anemone Heteractismagnifica peptide was obtained, and the kinetic parameters of its interaction with mammalian α-amylases were determined. Magnificamide inhibits α-amylases significantly stronger than the medical drug acarbose (Precose^TM or Glucobay^TM). Magnificamide is assumed to find application as a drug for prevention and treatment of metabolic disorders and type 2 diabetes mellitus.